Myovant Sciences

CompanySwitzerland

Myovant Sciences develops one asset, approved (estradiol in atrophic vaginitis). Mostly small molecule acting on ESR2, inflammation and ESR1; based in Switzerland.

1
Asset
Furthest: Approved; 7
Trials: 0
Signals

Pipeline

1

estradiol
Estrogen receptor agonist for hormone replacement
Approved, Small molecule, ESR2, Inflammation, atrophic vaginitis, hypogonadism

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms6
Trials7
Similar companies6

Updated 9 Oct 2026 · 69 sources